---
figid: PMC5961736__nihms964503f2
figtitle: Illustration of JAK/STAT signaling pathway that inspires effective therapeutic
  targets in lymphoma
organisms:
- Homo sapiens
pmcid: PMC5961736
filename: nihms964503f2.jpg
figlink: /pmc/articles/PMC5961736/figure/F2/
number: F2
caption: Illustration of JAK/STAT signaling pathway that inspires effective therapeutic
  targets in lymphoma. JAK/STAT pathway is a key mediator of cytokine signaling in
  both physiological and pathological conditions. Upon binding cytokines, basally
  inactive JAKs engaged to cytokine receptors are phosphorylated and thereby phosphorylate
  STATs. After being dimerization, phosphorylated STATs translocate from cytoplasm
  to nucleus and then bind to specific targeted genes. In turn, this pathway is negatively
  regulated by SOCS and CIS. The inhibitors targeting JAKs, STATs, or ILs are being
  expected to show expected treatment efficacy in some lymphomas. JAK, Janus kinase;
  STAT, signal transducer and activator of transcription; SHP, Src homology region
  2 domain-containing phosphatase; SOCS, suppressor of cytokine signaling; CIS, cytokine-inducible
  SH2-containing protein; PI3K, phosphoinositide-3-kinase; AKT, v-akt murine thymoma
  viral oncogene homolog1; mTOR, mechanistic target of Rapamycin; ERK, extracellular
  signal-regulated kinase; CCND1, cyclin D1; VEGF, vascular endothelial growth factor.
papertitle: Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers
  in Lymphoid Malignancies.
reftext: Ruifang Sun, et al. Crit Rev Oncog. ;22(5-6):527-557.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9207635
figid_alias: PMC5961736__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5961736__F2
ndex: 6c911e15-df0d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5961736__nihms964503f2.html
  '@type': Dataset
  description: Illustration of JAK/STAT signaling pathway that inspires effective
    therapeutic targets in lymphoma. JAK/STAT pathway is a key mediator of cytokine
    signaling in both physiological and pathological conditions. Upon binding cytokines,
    basally inactive JAKs engaged to cytokine receptors are phosphorylated and thereby
    phosphorylate STATs. After being dimerization, phosphorylated STATs translocate
    from cytoplasm to nucleus and then bind to specific targeted genes. In turn, this
    pathway is negatively regulated by SOCS and CIS. The inhibitors targeting JAKs,
    STATs, or ILs are being expected to show expected treatment efficacy in some lymphomas.
    JAK, Janus kinase; STAT, signal transducer and activator of transcription; SHP,
    Src homology region 2 domain-containing phosphatase; SOCS, suppressor of cytokine
    signaling; CIS, cytokine-inducible SH2-containing protein; PI3K, phosphoinositide-3-kinase;
    AKT, v-akt murine thymoma viral oncogene homolog1; mTOR, mechanistic target of
    Rapamycin; ERK, extracellular signal-regulated kinase; CCND1, cyclin D1; VEGF,
    vascular endothelial growth factor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PTPN11
  - SRC
  - FGR
  - FYN
  - YES1
  - PTPN6
  - NR0B2
  - KRAS
  - HRAS
  - NRAS
  - CISH
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - CCND1
  - MYC
  - BCL2
  - Tofacitinib
  - Ruxolitinib
  - Momelotinib
  - Pacritinib
  - Pyrimethamine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
